Chronic gout arthritis
Conditions
Interventions
1:Physical therapy, exercise, routine drugs
2:Routine drugs
Sponsors
The Affiliated Hospital of Qingdao University
Eligibility
Sex/Gender
Male
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Diagnosed as chronic gouty arthritis, according to the 2015 ACR/ELUAR clinical classification of gout diagnostic criteria; 2. Aged between 18 and 70 years old; 3. With visible tophi affecting 0-4 joints of bilateral lower extremities; 4. Patients with chronic pain, limitations in range of motion and daily activities over 1st toe, ankle, or knee joints); 5. Use febuxostat as urate-lowering drug, instead of other urate-lowering drugs; 6. Use smart mobile phone.
Exclusion criteria
Exclusion criteria: 1. Severe and unstable tophi: (1) visible tophi affecting more than 4 joints of bilateral lower extremities; (2) rapid growing tophi; (3) nerve compression by tophi; (4) connective tissue destructive effects; (5) tophaceous joints inflammation; 2. Patients with secondary hyperuricemia caused by hematological diseases, malignant tumors, kidney diseases or radiotherapy and chemotherapy; 3. Chronic gouty arthritis with acute attack for 3 days; 4. Arthritis caused by cellulitis, palindromic rheumatism, bacterial arthritis, pseudogout, ankylosing spondylitis, rheumatoid arthritis, rheumatoid arthritis, or osteoarthritis; 5. Other diseases: (1) Uncontrolled hypertension (resting blood pressure =160/100mmHg); (2) Uncontrolled diabetes (fasting gluscose>7.1 mmol/l, HbA1C>7.0 %); (3) Malignant tumor; (4) Organic disease e.g. unstable and severe cardiac disease, heart failure, unstable angina, myocardial infarction diagnosed by cardiologist; (5) Chronic obstructive pulmonary disease; (6) Recent cardiovascular disease. 6. Patients with active gastrointestinal ulcer, thyroid dysfunction, active tuberculosis and urinary calculi; 7. Patients with active liver disease or cirrhosis, or liver dysfunction; 8. Chronic kidney disease =3 stages (eGFR < 60ml/min), according to the simplified MDRD formula, GFR (ml/min 1.73m2) = 186 * (Scr) - 1.154 * (age) - 0.203 * (0.742 women); 9. Received joints injection or surgery over lower extremities in past 6 months; 10. Poor compliance and have difficulties in taking medicine, receiving physical therapy once per week, doing exercises for 3 months; 11. Patients who cannot walk independently with assistive device; 12. Patients with psychological disease cannot live independently and cooperate treatment; 13. Alcoholism and use illegal drugs; 14. Pregnant, lactating women or prepare to pregnancy women (including male subjects). 15.Participated in other research trials in past 3 months before this trail.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Serum urate; | — |
Secondary
| Measure | Time frame |
|---|---|
| ALT;AST;creatinine;fasting glucose;total cholesterol;triglycerides;urine pH;urine uric acid;tophi;tophi;pain;measure of range of motion;activities limitation, disability, pain resulted from foot discomfort;balance;mobility and function test in daily life;life quality;subjective percieved change of tratment;fitness; | — |
Countries
China
Contacts
Public ContactLi Changgui
The Affiliated Hospital of Qingdao University
Outcome results
None listed